Pavel Raifeld
Directeur Général chez INNOVIVA, INC.
Fortune : 184 206 $ au 31/05/2024
Profil
Pavel Raifeld is currently the Chief Executive Officer at Innoviva, Inc. He is also the Chief Executive Officer at Theravance Respiratory Co. LLC.
Additionally, he holds the position of Director at La Jolla Pharmaceutical Co. and Entasis Therapeutics Holdings, Inc. Mr. Raifeld previously worked as a Senior Member-Healthcare Investment Banking at Credit Suisse Securities (USA) LLC.
He holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from Harvard University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INNOVIVA, INC.
0,02% | 18/04/2024 | 11 666 ( 0,02% ) | 184 206 $ | 31/05/2024 |
Postes actifs de Pavel Raifeld
| Sociétés | Poste | Début |
|---|---|---|
| INNOVIVA, INC. | Directeur Général | 20/05/2020 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Directeur/Membre du Conseil | 11/07/2022 |
| LA JOLLA PHARMACEUTICAL COMPANY | Directeur/Membre du Conseil | 22/08/2022 |
Theravance Respiratory Co. LLC
 Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Directeur Général | - |
Anciens postes connus de Pavel Raifeld
| Sociétés | Poste | Fin |
|---|---|---|
Credit Suisse Securities (USA) LLC
 Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Pavel Raifeld
| Harvard University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Finance |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Theravance Respiratory Co. LLC
Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
